Here, we show for the first time that liposomal delivery of FLLL32, a STAT3 phosphorylation inhibitor, efficiently suppressed pancreatic cancer xenograft tumor growth, and sensitized pancreatic cancer cells to radiotherapy in vitro and in vivo by inhibiting STAT3 signaling in CSCs potentially. This evidence concerns the gene STAT3 and neoplasm.